• Return to Headlines

Relatively High Debt to EBITDA Ratio Detected in Shares of Ionis Pharmaceut in the Biotechnology Industry (IONS, BMRN, CELG, RGEN, ABBV)

By James Quinn

Below are the three companies in the Biotechnology industry with the highest debt to EBITDA ratios. This ratio indicates how many years of EBITDA would be necessary in order to pay back all the debt (assuming Debt and EBITDA are constant). Typically, this ratio is considered to be alarming when it is greater than 3.0 but this can vary and should be looked at within the context of the industry.

Ionis Pharmaceut ranks highest with a a debt to EBITDA ratio of 38.3. Following is Biomarin Pharmac with a a debt to EBITDA ratio of 22.2. Celgene Corp ranks third highest with a a debt to EBITDA ratio of 4.7.

Repligen Corp follows with a a debt to EBITDA ratio of 3.7, and Abbvie Inc rounds out the top five with a a debt to EBITDA ratio of 3.2.

SmarTrend is tracking the current trend status for Ionis Pharmaceut and will alert subscribers who have IONS in their portfolio or watchlist when shares have changed trend direction.

Keywords: highest debt to ebitda ratio ionis pharmaceut biomarin pharmac celgene corp repligen corp abbvie inc

Ticker(s): IONS BMRN CELG RGEN ABBV